Table 2 p63 and Ki67 Expression, Clinicopathologic Features and Outcome in 14 MECs
From: The prognostic significance of p63 and Ki-67 expression in myoepithelial carcinoma
Case | Age/sex | Site | Treatment | Recurrence | Metastasis | Follow-up, month (after first time treatment) | P63 | Ki67 |
|---|---|---|---|---|---|---|---|---|
1 | 45/M | Nasal septum | Surgery+ postoperative RT | No | No | NED(46 months) | - | - |
2 | 51/M | L Maxillary sinus | Preoperative RT+ Surgery+ postoperative RT+CT | Yes, 17 months | Yes, 20 months, lung | Dead due to MD(23 months) | + | - |
3 | 80/F | L Parotid gland | Surgery | Yes, 12 months | No | Dead due to cardiovascular disease (34 months) | + | + |
4 | 26/F | R Parotid gland | Surgery+ postoperative RT | No | No | NED(27 months) | - | - |
5 | 68/M | R Parotid gland | Surgery+ postoperative RT | Yes, 32 months | Yes, 40 months, lung | Dead due to MD(72 months) | + | + |
6 | 22/M | R submandibular gland | Surgery | No | No | NED(33 months) | - | - |
7 | 62/M | Larynx | Surgery+ postoperative RT | Yes, 38 months | Yes, 32 months, liver | Dead due to MD(39 months) | + | + |
8 | 40/F | L Maxillary sinus | Surgery+ postoperative RT+CT | Yes, 9 months | No | DOD(13 months) | + | ¯ |
9 | 58/M | L lung | Surgery+ postoperative RT+CT | Yes, 1 months | No | Alive with tumor (32 months) | - | - |
10 | 49/M | Nasal septum | Surgery+ postoperative RT | No | No | NED(12 months) | - | - |
11 | 39/M | L breast | Surgery | No | No | NED(36 months) | - | - |
12 | 65/F | R breast | Surgery | Yes,10 months | Yes, 32 months, lung | DOD (35 months) | + | + |
13 | 44/M | Palate | Surgery+ postoperative RT | Yes,16 months | No | NED(52 months) | - | - |
14 | 49/M | L lung | Surgery+ postoperative RT+CT | Yes,21 months | Yes, 37 months, brain | Dead of due to MD (40 months) | - | + |
15 | 53/M | L lung | Surgery+ postoperative RT+CT | No | No | NED(34 months) | - | - |
16 | 38/F | L Parotid gland | Surgery+ postoperative RT | No | No | NED(54 months) | - | - |